VYNE Therapeutics Inc. VYNE
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2018-01-25
VYNE Therapeutics Inc. statistics & valuation
Market cap$21.1M
P / S37.1×
P / B0.8×
Net margin-4646.1%
Return on equity-95.4%
Net cash$24.0M
Enterprise value USD-$2.9M
Return on capital-107.1%
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | -5219.1% | -8710.0% | -6900.5% | -7189.7% | -4179.5% | -1203.0% | -21641.8% | -703.9% | -645.9% | -2126.4% |
| Net margin | -4646.1% | -7950.9% | -6710.4% | -4865.8% | -7876.4% | -1217.4% | -21484.9% | -697.0% | -634.6% | -2087.2% |
| FCF margin | — | — | — | — | -6054.5% | -653.5% | -16806.3% | -650.7% | -616.5% | -340.7% |
| Return on assets | -87.8% | -59.5% | -29.1% | -56.9% | -109.4% | -272.6% | -117.3% | -53.0% | -43.5% | -33.5% |
| Return on equity | -95.4% | -76.5% | -32.1% | -74.4% | -150.8% | -681.6% | -541.6% | -80.5% | -42.4% | 47.8% |
| Debt / equity | 0.00× | 0.00× | 0.00× | 0.00× | 0.00× | 0.88× | 1.86× | — | — | — |
| Current ratio | 12.53 | 4.35 | 12.73 | 4.10 | 3.43 | 4.01 | 2.61 | 14.62 | 8.17 | 8.08 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.